MPZL3 and obesity due to melanocortin 4 receptor deficiency: Together, these data demonstrate that Mpzl3 inhibition is a potential therapeutic approach for treatment of obesity and related comorbid conditions, including insulin resistance, hyperlipidemia and cardiovascular dysfunction.